Adaptimmune Therapeutics PLC - ADR (OQ:ADAP)

May 01, 2024 12:00 pm ET
Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024
Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - May 1, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the first quarter ended March 31, 2024, before the US markets open on Wednesday, May 15, 2024. Following the announcement, the Company will host a live webcast at 8:00 a.m. EDT (1:00 p.m. BST) that same day.
Apr 12, 2024 08:00 am ET
Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated
Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - April 12, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced that its strategic collaboration with Genentech entered in 2021, has been terminated.
Mar 27, 2024 07:30 pm ET
Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet
Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - March 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced that The Lancet published the company's pivotal Phase 2 data with afami-cel. The article, titled "SPEARHEAD-1: a single-arm phase 2 trial of afamitresgene autoleucel (afami-cel) in advanced synovial sarcoma and myxoid/round cell liposarcoma," details clinical and translational results from afami-cel's SPEARHEAD-1 trial (NCT04044768).
Mar 06, 2024 07:00 am ET
Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates
Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - March 6, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update on the progress made in establishing its sarcoma franchise.
Feb 27, 2024 08:00 am ET
Feb 21, 2024 04:00 pm ET
Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 21, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the fourth quarter and full year ended December 31, 2023, before the US markets open on Wednesday, March 6, 2024. Following the announcement, the Company will host a live webcast at 8:00 a.m. EST (1:00 p.m. GMT) that same day.
Jan 31, 2024 04:44 pm ET
Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 31, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review its Biologics License Application (BLA) for afami-cel, an investigational engineered T-cell therapy for advanced synovial sarcoma. The application has a Prescription Drug User Fee Act (PDUFA) target action date of August 4, 2024.
Jan 04, 2024 07:37 am ET
Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 4, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today announced the Company's plans for its emerging sarcoma franchise including projections for peak US sales of up to $400 million.
Dec 06, 2023 07:00 am ET
Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - December 6, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today announced the completion of the submission of its rolling Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for afami-cel, an investigational engineered T-cell therapy for advanced synovial sarcoma. Afami-cel is eligible for a Priority Review, which would shorten the FDA's review of the application to 8 months versus a standard review timeline of 12 months.
Nov 29, 2023 08:00 am ET
Adaptimmune Receives Transfer of IND for Lete-cel Program
Philadelphia, Pennsylvania. and Oxford, United Kingdom--(Newsfile Corp. - November 29, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, announces the transfer of the IND for letetresgene autoluecel (lete-cel) from GSK to Adaptimmune for the pivotal IGNYTE-ESO (NCT03967223) clinical trial.
Nov 08, 2023 07:30 am ET
Adaptimmune Reports Third Quarter Financial Results and Business Update
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 8, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today reported financial results for the third quarter ended September 30, 2023 and provided a business update.
Nov 08, 2023 07:05 am ET
Adaptimmune Selects ADP-600 as Clinical Candidate for Best-in Class PRAME Strategy
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 8, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, provides a progress update on its PRAME program (ADP-600).
Oct 31, 2023 08:00 am ET
Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - October 31, 2023) - Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, to present outcome data from Cohort 1 of its pivotal SPEARHEAD-1 trial at the Connective Tissue Oncology Society (CTOS) annual meeting in Dublin, Ireland. These data will be shared in an oral presentation by SPEARHEAD-1 investigator, Brian A. Van Tine, MD, PhD, Washington University School of Medicine in St. Louis, on Friday, November 3rd, during Session 5: Immunology & Immunotherapy from 9-10 a.m. GMT / 5-6 a.m. EDT (Paper 30).
Oct 31, 2023 08:00 am ET
Adaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - October 31, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, is reporting the outcome of a protocol-defined interim analysis of data from the pivotal IGNYTE-ESO trial with lete-cel for people with synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) who received ≥ 2 prior lines of therapy.
Oct 25, 2023 08:06 am ET
Adaptimmune to Report Q3 2023 Financial and Business Updates on Wednesday, November 8, 2023
Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - October 25, 2023) - Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the third quarter ended September 30, 2023, before the US markets open on Wednesday, November 8, 2023. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EST (1:00 p.m. GMT) that same day.
Oct 23, 2023 04:15 am ET
Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - October 23, 2023) - Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, presented clinical and translational data from its Phase 1 SURPASS clinical trial (NCT04044859) investigating the next-generation engineered T-cell therapy ADP-A2M4CD8 at the Annual European Society for Medical Oncology (ESMO) Congress today. The oral presentation was presented by Dr. Victor Moreno of START Madrid-FJD, Fundación Jiménez Díaz Hospital, in the proffered paper session - investigational monotherapy.
Sep 11, 2023 08:00 am ET
Dr. Karen Chagin Joins Adaptimmune as Senior Vice President of Early-Stage Development
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - September 11, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today announces that Karen Chagin, MD has joined the Company as its Senior Vice President of Early-Stage Development. Dr. Chagin will oversee the Company's early-stage pipeline activities from pre-IND and IND activities through Phase 1 clinical trials.
Aug 09, 2023 07:29 am ET
Adaptimmune Reports Second Quarter Financial Results and Business Update
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 9, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today reported financial results for the second quarter ended June 30, 2023 and provided a business update.
Aug 03, 2023 01:24 pm ET
Adaptimmune to Report Q2 2023 Financial and Business Updates on Wednesday, August 9, 2023
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 3, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the second quarter ended June 30, 2023, before the US markets open on Wednesday, August 9, 2023. Following the announcement, the Company will host a live conference call at 8:00 a.m. EDT (1:00 p.m. BST) that same day.
Jun 01, 2023 03:29 pm ET
Adaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - June 1, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP) today announced completion of an all-stock transaction in which Adaptimmune has combined with TCR² Therapeutics Inc. (NASDAQ: TCRR) to create a preeminent T-cell therapy company to treat solid tumors.
May 25, 2023 05:00 pm ET
Adaptimmune Announces 70% of People with Advanced Synovial Sarcoma Who Respond to Afami-cel are Alive Two Years Post-Treatment; Data from Cohort 1 of SPEARHEAD-1 to be Presented at ASCO
Philadelphia, Pennsylvania--(Newsfile Corp. - May 25, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will present data from Cohort 1 of its pivotal trial SPEARHEAD-1 (NCT04044768) for people with advanced synovial sarcoma at the American Society of Clinical Oncology's (ASCO) annual meeting. The poster, titled "The SPEARHEAD-1 trial of afamitresgene autoleucel: Analysis of overall survival in advanced synovial sarcoma," will be presented by Dr. Brian Van Tine of the Washington University School of Medicine at 1:15 p.m. CDT, Saturday, June 3rd, in Hall A, Sarcoma track.
May 12, 2023 07:29 am ET
Adaptimmune Reports First Quarter Financial Results and Business Update
Philadelphia, Pennsylvania. and Oxford, United Kingdom--(Newsfile Corp. - May 12, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today reported financial results for the first quarter ended March 31, 2023 and provided a business update.
Apr 28, 2023 12:00 pm ET
Adaptimmune to Report Q1 2023 Financial and Business Updates on Friday, May 12, 2023
Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - April 28, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the first quarter ended March 31, 2023, before the US markets open on Friday, May 12, 2023. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EDT (1:00 p.m. BST) that same day.
Apr 13, 2023 01:00 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVT, PTRS, ROCC, ADAP
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Cvent Holding Corp. (NASDAQ: CVT)’s...
Apr 12, 2023 05:25 pm ET
ALERT: The M&A Class Action Firm Continues Investigating the Merger – CNXC, INDT, HSKA, ADAP
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Apr 11, 2023 01:39 pm ET
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates ROCC, KBAL, ADAP, TCRR
NEW YORK, April 11, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Apr 11, 2023 08:00 am ET
Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - April 11, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in T-cell therapy to treat cancer, today announced entry into a transition agreement with GSK plc (LSE: GSK) (NYSE: GSK) regarding the return of rights and materials comprised within the PRAME and NY-ESO cell therapy programs.
Apr 06, 2023 11:25 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RADI, ADAP, TCRR
NEW YORK, April 6, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Apr 05, 2023 04:00 pm ET
STOCKHOLDER ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – MLVF, SAL, ADAP, BRBW
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Mar 30, 2023 10:03 am ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Diffusion Pharmaceuticals Inc. (Nasdaq- DFFN), U.S. Xpress Enterprises, Inc. (NYSE – USX), TCR² Therapeutics In
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Mar 30, 2023 09:41 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates USX, RADI, ROCC, ADAP
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: U.S. Xpress Enterprises, Inc. (NYSE:...
Mar 29, 2023 04:30 pm ET
SHAREHOLDER ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – ADAP, SAL, BRBW, MLVF
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Mar 28, 2023 11:40 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ROCC, RADI, ADAP, TCRR
NEW YORK, March 28, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Mar 24, 2023 08:51 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RADI, DSEY, ADAP, TCRR
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Radius Global Infrastructure, Inc....
Mar 23, 2023 02:24 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DSEY, ADAP, TCRR
NEW YORK, March 23, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Mar 22, 2023 04:06 pm ET
ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – MLVF, ADAP, BRBW, SAL
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Mar 19, 2023 10:16 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SGEN, ADAP, PRVB, XM
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Seagen Inc. (NASDAQ: SGEN)’s sale to...
Mar 18, 2023 08:11 pm ET
Lifshitz Law PLLC Announces Investigations of SGEN, PRVB, KBAL, and ADAP
Seagen Inc. (NASDAQ: SGEN) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of SGEN to Pfizer Inc. for $229.00 per share in cash. If you are a SGEN investor, and would like...
Mar 16, 2023 11:42 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates JNCE, ADAP, TCRR
NEW YORK, March 16, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Mar 15, 2023 04:50 pm ET
ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – ADAP, LBC, SAL, BRBW
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and...
Mar 09, 2023 09:06 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KBAL, DSEY, ADAP, TCRR
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Kimball International, Inc. (NASDAQ:...
Mar 08, 2023 07:21 pm ET
Lifshitz Law PLLC Announces Investigations of DSEY, KBAL, ADAP, and TCRR
Diversity Holdings, Ltd. (NASDAQ: DSEY) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of DSEY to Solenis for $8.40 per share in cash. If you are a DSEY investor,...
Mar 08, 2023 04:00 pm ET
STOCKHOLDER ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – LBC, ADAP, BRBW, SAL
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and...
Mar 06, 2023 08:30 am ET
ADAP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Adaptimmune Therapeutics plc Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Adaptimmune Therapeutics plc (NASDAQ: ADAP) and TCR² Therapeutics Inc. is fair to Adaptimmune shareholders. Under the terms of the agreement, TCR² stockholders will receive 1.5117 Adaptimmune ADS for each TCR² share. Following the closing of the transaction, Adaptimmune shareholders will own approximately 75% of the combined company.
Mar 06, 2023 06:30 am ET
Adaptimmune Reports Fourth-Quarter and Full Year Financial Results and Business Update
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 6, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update.
Mar 06, 2023 06:00 am ET
Adaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors
Philadelphia, Pennsylvania, Oxford, United Kingdom, and Cambridge, Massachusetts--(Newsfile Corp. - March 6, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP) and TCR² Therapeutics Inc. (NASDAQ: TCRR), today announced entry into a definitive agreement under which Adaptimmune will combine with TCR² in an all-stock transaction to create a preeminent cell therapy company focused on treating solid tumors. The combination provides extensive benefits for clinical development and product delivery supported by complementary technology platforms. As a result, and following the closing of the transaction, it is anticipated that the combined company's cash runway will extend into 2026.
Feb 22, 2023 08:00 am ET
Adaptimmune to Report Q4 and Full Year 2022 Financial and Business Updates on Monday, March 6, 2023
Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - February 22, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the fourth quarter and full year ended December 31, 2022, before the US markets open on Monday, March 6, 2023. Following the announcement, the Company will host a live webcast at 8:00 a.m. EST (1:00 p.m. GMT) that same day.
Feb 16, 2023 08:00 am ET
Adaptimmune Announces Changes to Board of Directors
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 16, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in T-cell therapy to treat cancer, today announced that Kristen M. Hege, M.D. will join its board of directors. In addition, Dr. Tal Zaks, who has served as a Non-Executive Director since 2016, will be stepping down from the board of directors.
Jan 09, 2023 08:00 am ET
Publication of Data from Adaptimmune's Completed Phase 1 Trial with Afami-cel in Nature Medicine Demonstrating an Acceptable Safety Profile and Encouraging Responses in Synovial Sarcoma
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 9, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today announced the publication of data in the current issue of Nature Medicine from its completed, multi-center, open-label, first-in-human, dose escalation Phase 1 trial with afami-cel (NCT03132922). Afami-cel is an investigational, engineered T-cell receptor (TCR) T-cell therapy targeting the cancer testis antigen MAGE-A4 which is expressed across multiple solid tumor indications.
Dec 23, 2022 01:20 pm ET
Adaptimmune Announces Initiation of Biologics License Application (BLA) Submission for Afami-cel, Its First-Gen Engineered TCR T-cell Therapy targeting MAGE-A4, For the Treatment of Synovial Sarcoma
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - December 23, 2022) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today reports that it has initiated the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for afami-cel for use as a single-dose regimen for the treatment of advanced synovial sarcoma.
Nov 18, 2022 08:00 am ET
Data from Cohort 1 of SPEARHEAD-1 Trial at CTOS Continue to Support BLA Submission for Afami-cel in Synovial Sarcoma - Response Rate and Durability Remain Consistent
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 18, 2022) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, is presenting clinical and translational data from the final analyses of the pivotal SPEARHEAD-1 trial (Cohort 1) with afamitresgene autoleucel (afami-cel) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) at the Connective Tissue Oncology Society (CTOS) annual meeting taking place this week in Vancouver, BC. The data will be shared in an oral presentation by SPEARHEAD-1 investigator, Brian A. Van Tine, MD, PhD, Washington University School of Medicine in St. Louis, on Friday, November 18th, during Session 9: Immunology & Immunotherapy at 4:39 p.m. UTC/ 7:30 p.m. EST (Paper 61).​
Nov 08, 2022 07:30 am ET
Adaptimmune Reports Third-Quarter Financial Results and Business Update
Adaptimmune will focus on programs in MAGE-A4 and PRAME, two of the most validated T-Cell targets in solid tumors 
Nov 08, 2022 07:00 am ET
Adaptimmune Reports Increased Response Rate and Durability of Response in Its Phase 1 SURPASS trial; ORR Now 52% Across Ovarian, Urothelial, and Head & Neck Cancers
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 8, 2022) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today reports updated clinical data from its MAGE-A4 franchise. Clinical data continue to support the potential of Adaptimmune's engineered T-cell therapies for people with cancer across multiple solid tumor indications. The company will provide further details on a call to be held today, November 8, 2022, at 8:00 a.m. EST (1:00 p.m. GMT) during which management will be available for Q&A.
Oct 27, 2022 12:27 pm ET
Adaptimmune to Report Q3 2022 Financial and Business Updates on Tuesday, November 8, 2022
Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - October 27, 2022) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the third quarter ended September 30, 2022, before the US markets open on Tuesday, November 8, 2022. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EST (1:00 p.m. GMT) that same day.
Oct 25, 2022 08:00 am ET
Adaptimmune Enhances Its Pipeline of Wholly Owned Cell Therapies for Cancer with Transfer of PRAME and NY-ESO Target Programs from GSK
Adaptimmune gains full control of late-stage preclinical optimized PRAME TCR; IND-ready in 2023 –
Sep 27, 2022 06:25 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adaptimmune Therapeutics plc - ADAP
Pomerantz LLP is investigating claims on behalf of investors of Adaptimmune Therapeutics plc (“Adaptimmune” or the “Company”) (NASDAQ: ADAP).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....
Sep 09, 2022 07:00 am ET
Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - September 9, 2022) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today announces positive data from its signal-finding Phase 1 SURPASS trial. The data will be presented at the European Society for Medical Oncology (ESMO) 2022 Congress by SURPASS investigator, David Hong, M.D., of The University of Texas MD Anderson Cancer Center. In conjunction with ESMO 2022, Adaptimmune will provide an update on the SURPASS Phase 1 data and outline future plans for its SURPASS family of trials, during a live virtual event to be held at 8 a.m. EDT today (details to join below).
Aug 25, 2022 08:00 am ET
Adaptimmune to Host Live, Virtual Event to Review Phase 1 SURPASS Trial Data and Outline Plans for Further Development in SURPASS Family of Trials
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 25, 2022) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will provide an update on its Phase 1 SURPASS trial data and outline future plans for the SURPASS family of trials during a live virtual event to be held on Friday, September 9th, at 8 a.m. EDT (1 p.m. BST).
Aug 04, 2022 07:30 am ET
Adaptimmune Reports Second-Quarter Financial Results and Business Update
Philadelphia, Pennsylvania, and Oxford, United Kingdom--(Newsfile Corp. - August 4, 2022) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today reported financial results for the second quarter ended June 30, 2022 and provided a business update. For the three months ended June 30, 2022, Revenue was $5.5 million, Total Operating Expenses (Research and Development and General and Administrative) were $49.3 million, and Net Loss was $44.5 million.
Jul 21, 2022 08:00 am ET
Adaptimmune to Report Q2 2022 Financial Results and Business Updates on Thursday, August 4, 2022
Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - July 21, 2022) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the second quarter ended June 30, 2022, before the US markets open on Thursday, August 4, 2022. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EDT (1:00 p.m. BST) that same day.
May 26, 2022 05:00 pm ET
Clinical Responses Reported across Patient Subgroups with Adaptimmune's Cell Therapy, Afami-cel, Confirming Potential for People with Rare Sarcomas - BLA Submission On-Track
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 26, 2022) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, presented pooled analyses from its Phase 1 and pivotal trials with afami-cel for synovial sarcoma and myxoid/round cell liposarcoma (MRCLS) at the American Society of Clinical Oncology (ASCO) annual meeting.
May 16, 2022 05:00 pm ET
Preclinical Proof-of-Concept Data Supporting Future Clinical Development of Two New Cell Therapies Being Presented by Adaptimmune at ASGCT
Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, is presenting preclinical proof-of-concept data from its second next-generation SPEAR T-cell (ADP-A2M4N7X19) targeting MAGE-A4, and novel tumor-infiltrating...
May 09, 2022 07:30 am ET
Adaptimmune Reports First Quarter Financial Results and Business Update
PHILADELPHIA and OXFORDSHIRE, United Kingdom, May 09, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, today reported financial results for the first quarter ended March 31, 2022 and...
May 04, 2022 08:00 am ET
Adaptimmune Announces Appointment of Joanna Brewer as Chief Scientific Officer
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Dr. Joanna (Jo) Brewer as Chief Scientific Officer (CSO) effective immediately. “Jo Brewer is an exceptional scientific...
Apr 28, 2022 04:30 pm ET
Adaptimmune to Report Q1 2022 Financial Results and Business Updates on Monday, May 9, 2022
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the first quarter ended March 31, 2022, before the US markets open on Monday, May 9, 2022....
Apr 08, 2022 01:00 pm ET
Adaptimmune Presents MAGE-A4 Expression Data from its Screening Protocol at AACR Confirming Expression Across a Broad Range of Solid Tumors
Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, presented data from the multinational, multicenter, screening protocol (NCT02636855) at the American Association for Cancer Research (AACR) annual meeting in a...
Mar 14, 2022 09:31 am ET
Thinking about buying stock in Turquoise Hill Resources, Mullen Automotive, Frontier Group, Adaptimmune Therapeutics, or Nokia?
NEW YORK, March 14, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TRQ, MULN, ULCC, ADAP, and NOK.
Mar 14, 2022 08:00 am ET
Adaptimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Business Update
PHILADELPHIA and OXFORDSHIRE, United Kingdom, March 14, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, today reported financial results for the fourth quarter and full year ended...
Mar 08, 2022 12:35 pm ET
Adaptimmune to Report Q4 and Full Year 2021 Financial Results and Business Updates on Monday, March 14, 2022
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the fourth quarter and year ended December 31, 2021, before the US markets open on Monday, March...
Jan 26, 2022 08:00 am ET
Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Cintia Piccina as Chief Commercial Officer effective January 31, 2022. “I am delighted to welcome Cintia to our leadership...
Nov 12, 2021 07:00 am ET
Translational Data at SITC 2021 from Adaptimmune’s Phase 1 SURPASS Trial Indicate Adding AKTi to Manufacturing May Contribute to Sustained Antitumor Activity of Next-gen SPEAR T-cells
Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, will present translational data from the Phase 1 SURPASS trial during the poster session at the Society for Immunotherapy of Cancer (SITC) annual meeting in...
Nov 11, 2021 09:00 am ET
Adaptimmune Reports Positive Results from its Pivotal SPEARHEAD-1 Trial in Patients with Synovial Sarcoma and MRCLS at CTOS
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report updated clinical and translational data from its pivotal SPEARHEAD-1 trial with afamitresgene autoleucel (afami-cel, formerly ADP-A2M4) in patients...
Nov 04, 2021 07:30 am ET
Adaptimmune Reports Third Quarter Financial Results and Business Update
PHILADELPHIA and OXFORD, United Kingdom, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, today reported financial results for the third quarter ended September 30, 2021, and...
Oct 21, 2021 08:00 am ET
Adaptimmune to Report Q3 2021 Financial Results and Business Update on Thursday, November 4, 2021
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide a business update for the third quarter ended September 30, 2021, before the US markets open on Thursday, November 4,...
Oct 05, 2021 08:00 am ET
Adaptimmune to Present Data Updates at Upcoming CTOS and SITC Meetings
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will present clinical and translational data from the Phase 2 SPEARHEAD-1 trial at the Connective Tissue Oncology Society (CTOS) meeting. The Company will also...
Sep 15, 2021 09:31 am ET
Thinking about buying stock in Microvast, FuelCell Energy, Workhorse Group, Adaptimmune Therapeutics, or American Resources?
NEW YORK, Sept. 15, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MVST, FCEL, WKHS, ADAP, and AREC.
Sep 13, 2021 08:30 am ET
Thinking about buying stock in Leap Therapeutics, Aterian, Hepion Pharmaceuticals, Adaptimmune Therapeutics, or Endo International?
NEW YORK, Sept. 13, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LPTX, ATER, HEPA, ADAP, and ENDP.
Sep 13, 2021 07:00 am ET
Adaptimmune Announces Clinical Responses across Five Solid Tumor Indications with an Overall Response Rate of 36% and Promising Early Durability from its Next-Generation SURPASS Trial
Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, announced updated data from its Phase 1 SURPASS trial in multiple solid tumors to be presented in a digital poster at the upcoming European Society for Medical...
Sep 07, 2021 08:30 am ET
Thinking about buying stock in Adaptimmune Therapeutics, Ziopharm Oncology, Uniqure NV, GlycoMimetics, or AbCellera Biologics?
NEW YORK, Sept. 7, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ADAP, ZIOP, QURE, GLYC, and ABCL.
Sep 07, 2021 07:00 am ET
Adaptimmune Enters into a Strategic Collaboration with Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, announced today that it has entered into a strategic collaboration and license...
Sep 05, 2021 06:15 am ET
Adaptimmune Updates Data from its Phase 1 Trial for Liver Cancer at ILCA Showing Clinical Benefit
Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, announced updated data from its Phase 1 ADP-A2AFP trial for patients with liver cancer at ILCA. “We have seen significant antitumor activity with this...
Aug 09, 2021 04:00 pm ET
Adaptimmune Reports Second Quarter Financial Results and Business Update
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, today reported financial results for the second quarter ended June 30, 2021 and...
Jul 28, 2021 08:11 am ET
Adaptimmune to Report Q2 2021 Financial Results and Business Update on Monday, August 9, 2021
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide a business update for the second quarter ended June 30, 2021, after the US markets close on Monday, August 9, 2021....
May 19, 2021 05:00 pm ET
Two Complete Responses and Response Rate of 41% for People with Synovial Sarcoma Reported at ASCO in Adaptimmune’s Phase 2 SPEARHEAD-1 Trial
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report initial data from its Phase 2 SPEARHEAD-1 trial, with afamitresgene autoleucel (afami-cel, formerly ADP-A2M4), at the American Society of Clinical...
May 11, 2021 08:00 am ET
First Preclinical Data from Adaptimmune’s Mesothelin HiT Program at ASGCT Demonstrate Antigen-specific Tumor Cell Killing in vitro and Complete Tumor Regression in an Animal Model
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, reported preclinical data from its HiT targeting mesothelin, being co-developed with Astellas, during a poster presentation at the American Society for Cell and...
May 06, 2021 07:30 am ET
Adaptimmune Reports First Quarter Financial Results and Business Update
PHILADELPHIA and OXFORD, United Kingdom, May 06, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, today reported financial results for the first quarter ended March 31, 2021 and...
Apr 27, 2021 04:30 pm ET
Adaptimmune to Present First Preclinical Data from its HLA-independent TCR (HiT) Platform at ASGCT
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report initial preclinical data from its HLA Independent TCR (HiT) targeting mesothelin, being co-developed with Astellas, during a poster presentation at...
Apr 22, 2021 08:00 am ET
Adaptimmune to Report Q1 2021 Financial Results and Business Update on Thursday, May 6, 2021
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide a business update for the first quarter ended March 31, 2021, before the US markets open on Thursday, May 6, 2021....
Feb 25, 2021 07:30 am ET
Adaptimmune Reports Fourth Quarter / Full Year 2020 Financial Results and Business Update
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, today reported financial results for the fourth quarter and year ended December 31, 2020, and provided a business update. “We are building the cell therapy...
Feb 11, 2021 08:00 am ET
Adaptimmune to Report Fourth Quarter/ Full Year 2020 Financial Results and Business Updates on Thursday, February 25, 2021
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the fourth quarter and year ended December 31, 2020, before the US markets open on Thursday,...
Nov 20, 2020 07:30 am ET
Adaptimmune to Showcase Market Potential for SPEAR T-cell Portfolio and Pipeline with Multiple Cell Therapy Platforms During Virtual Investor Day
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Nov. 20, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, will host a virtual Investor Day today, which will feature the Company’s Senior...
Nov 19, 2020 09:00 am ET
Durable Responses with ADP-A2M4 in Synovial Sarcoma with Confirmed Responses in 44% of Patients and Disease Control Rate of 94% Presented at CTOS
Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, presented durability of response data from patients with synovial sarcoma from the Phase 1 ADP-A2M4 trial at the virtual Connective Tissue Oncology Society...
Nov 12, 2020 08:00 am ET
Adaptimmune to Host Virtual Investor Day on Friday, November 20th
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will host a virtual Investor Day on November 20, 2020 at 8AM EST/ 1PM GMT. A link to register is available HERE and further details are on the Investor Relations...
Nov 09, 2020 03:18 pm ET
Two Confirmed Responses and Five out of Six Patients with Initial Tumor Reductions from Early Dose Cohorts of SURPASS Trial, Presented at SITC
Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, presented data from the dose escalation cohorts of its Phase 1 SURPASS trial using ADP-A2M4CD8 in a poster at the Society for the Immunotherapy of Cancer...
Nov 05, 2020 07:30 am ET
Adaptimmune Reports Q3 Financial Results and Business Update
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, today reported financial results and provided a business update for the third...
Oct 22, 2020 08:00 am ET
Adaptimmune to Report Q3 Financial Results and Business Update on Thursday, November 5, 2020
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide a business update for Q3 2020, before the U.S. markets open on Thursday, November 5, 2020. Following the announcement,...
Oct 15, 2020 04:40 pm ET
Adaptimmune Provides Full Contents of its SITC Abstract for the Phase 1 SURPASS Trial
Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in cell therapy to treat cancer is aware of the early release of the abstract entitled “Initial safety, efficacy, and product attributes from the SURPASS trial with ADPA2M4CD8, a...
Aug 28, 2020 10:30 am ET
Promising Data from Phase 1 Trial with ADP-A2AFP in Liver Cancer at the International Liver Congress Confirm Safety Profile and Demonstrate Potential Benefit for Patients
Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in cell therapy to treat cancer, presented data from its Phase 1 trial with SPEAR T-cells targeting AFP at the virtual International Liver Congress (ILC). One patient out of four...
Aug 06, 2020 07:30 am ET
Adaptimmune Reports Q2 Financial Results and Business Update
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, today reported financial results and provided a business update for the second...
Jul 23, 2020 04:00 pm ET
Adaptimmune Granted Access to PRIority MEdicines (PRIME) Regulatory Support by the European Medicines Agency for ADP-A2M4 for the Treatment of Synovial Sarcoma
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, announced that the European Medicines Agency (EMA) has granted access to the PRIME initiative to the Company for ADP-A2M4 for the treatment of synovial sarcoma....
Jul 22, 2020 08:00 am ET
Adaptimmune to Report Q2 Financial Results and Business Update on Thursday, August 6, 2020
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide a business update for Q2 2020, before the U.S. markets open on Thursday, August 6, 2020. Following the announcement, the...
Jun 04, 2020 10:45 am ET
Adaptimmune Therapeutics plc Announces Closing of Public Offering of American Depositary Shares
Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in cell therapy to treat cancer, today announced the closing of its previously announced underwritten public offering of its American Depositary Shares (“ADSs”).  Adaptimmune sold...
Jun 02, 2020 09:31 am ET
Thinking about buying stock in Tenax Therapeutics, Allena Pharmaceuticals, Trevena, Adaptimmune Therapeutics, or Aurora Cannabis?
NEW YORK, June 2, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TENX, ALNA, TRVN, ADAP, and ACB.
Jun 01, 2020 09:39 pm ET
Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares
Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in cell therapy to treat cancer, today announced the pricing of an underwritten public offering of 20,500,000 of its American Depositary Shares (“ADSs”) at a price to the public...
Jun 01, 2020 06:00 am ET
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in cell therapy to treat cancer, today announced that it intends to offer and sell 12,500,000 American Depositary Shares (“ADSs”) in an underwritten public offering. The offering...
May 29, 2020 09:31 am ET
Thinking about buying stock in Adaptimmune Therapeutics, MEI Pharma, Dynavax Technologies, AIM ImmunoTech, or Meridian Bioscience?
NEW YORK, May 29, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ADAP, MEIP, DVAX, AIM, and VIVO.
May 29, 2020 07:30 am ET
SPEAR T-cells Targeting MAGE-A4 Demonstrate New Responses in Esophagogastric Junction (EGJ), Lung, and Head and Neck Cancers – Late Stage Development Initiated in EGJ Cancer
PHILADELPHIA and OXFORDSHIRE, United Kingdom, May 29, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, presented updated data from its ADP-A2M4 Phase 1 trial at the American Society for...
May 14, 2020 07:30 am ET
Adaptimmune Reports Q1 Financial Results
PHILADELPHIA and OXFORDSHIRE, United Kingdom, May 14, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, reported financial results for the first quarter ended March 31, 2020. “After...
May 12, 2020 09:31 am ET
Thinking about buying stock in Adaptimmune Therapeutics, Upwork, Eldorado Resorts, Co-Diagnostics, or Delta Air Lines?
NEW YORK, May 12, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ADAP, UPWK, ERI, CODX, and DAL.
May 12, 2020 08:00 am ET
SPEAR T-cells Derived from Stem-Cells Kill Cancer Targets - Adaptimmune Presents Advances from its Allogeneic Platform at ASGCT Annual Meeting
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, presented advances from its “off-the-shelf” or allogeneic platform at the American Society for Gene and Cell Therapy (ASGCT) Annual meeting which kicked off in...
Apr 29, 2020 08:00 am ET
Adaptimmune to Report Q1 Financial Results on Thursday, May 14, 2020
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results for Q1 2020, before the U.S. markets open on Thursday, May 14, 2020. Following the announcement, the Company will host a live...
Apr 28, 2020 08:00 am ET
Positive Opinion for Orphan Drug Designation for ADP-A2M4 in the European Union for the Treatment of Soft Tissue Sarcoma from EMA' Committee of Orphan Medicinal Products
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, announced that the European Medicine Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion for Orphan Drug Designation for...
Feb 27, 2020 07:30 am ET
Adaptimmune Reports Fourth Quarter / Full Year 2019 Financial Results and Business Update
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, today reported financial results for the fourth quarter and year ended December 31, 2019, and provided a business update. “The last 12 months...
Feb 20, 2020 04:00 pm ET
Adaptimmune to Report Full Year / Q4 2019 Financial Results and Business Update on Thursday, February 27, 2020
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results for the Full Year / Fourth Quarter 2019 and provide a business update, before the U.S. markets open on Thursday, February 27, 2020....
Feb 18, 2020 08:00 am ET
Adaptimmune Announces Appointment of Gavin Wood as Chief Financial Officer
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Gavin Wood as Chief Financial Officer (CFO), effective April 1, 2020. “I am delighted to welcome Gavin to Adaptimmune. He...
Feb 07, 2020 04:05 pm ET
Adaptimmune Therapeutics plc Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional American Depositary Shares
Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced that the underwriters of its previously announced public offering of 21,000,000 American Depositary Shares (“ADSs”), which...
Jan 24, 2020 04:30 pm ET
Adaptimmune Therapeutics plc Announces Closing of Public Offering of American Depositary Shares
Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced the closing of its previously announced underwritten public offering of its American Depositary Shares (“ADSs”).  Adaptimmune...
Jan 22, 2020 08:48 am ET
Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares
Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced the pricing of an underwritten public offering of 21,000,000 of its American Depositary Shares (“ADSs”) at a price to the public...
Jan 21, 2020 04:08 pm ET
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced that it intends to offer and sell American Depositary Shares (“ADSs”) in an underwritten public offering. The offering is subject to market...
Jan 14, 2020 02:08 am ET
Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas"), through its wholly-owned subsidiary Universal Cells, Inc, and Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, announced...
Jan 13, 2020 08:30 am ET
Adaptimmune Appoints Elliot Norry as Chief Medical Officer and Makes Changes to R&D Leadership
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, today announced the appointment of Dr. Elliot Norry as Senior Vice President and Chief Medical Officer (CMO) effective immediately, and additional changes to its...
Jan 13, 2020 02:00 am ET
Adaptimmune Announces that SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, reported today, at the 38th JP Morgan Healthcare Conference, two confirmed Partial Responses (PRs) – one in a patient with liver cancer and one in a patient with...
Dec 03, 2019 08:30 am ET
Regenerative Medicine Advanced Therapy Designation Granted by FDA to ADP‑A2M4 for the Treatment of Synovial Sarcoma
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for ADP-A2M4 for...
Nov 16, 2019 02:00 am ET
Updated Data from Phase 1 ADP-A2M4 Trial Demonstrating Continued Clinical Benefit for People with Synovial Sarcoma
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented updated data from people with synovial sarcoma treated in the ongoing Phase 1 trial with ADP-A2M4. The oral presentation by Brian Van Tine, MD, PhD of...
Nov 06, 2019 07:30 am ET
Adaptimmune Reports Third Quarter 2019 Financial Results and Business Update
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today reported financial results and business highlights from Q3 2019....
Nov 01, 2019 08:00 am ET
Adaptimmune to Report Third Quarter 2019 Financial Results and Business Update on Wednesday, November 6, 2019
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will report financial results for the Third Quarter 2019 and provide a business update, before the U.S. markets open on Wednesday, November 6, 2019. Following...
Oct 09, 2019 08:00 am ET
Adaptimmune and Cryoport Announce Agreement to Ensure Safe and Fully Monitored Transport of Adaptimmune’s Cell Therapies
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, and Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport"), the world's leading temperature-controlled logistics solutions company dedicated to the life...
Oct 01, 2019 08:00 am ET
Adaptimmune Announces Appointment of Michael Garone as Interim Chief Financial Officer
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, announces the appointment of Michael Garone as interim Chief Financial Officer (CFO) effective immediately. “We are thrilled to announce that Michael Garone...
Sep 30, 2019 08:45 am ET
Clear Benefit for Patients with Synovial Sarcoma Demonstrated in Updated Data from Ongoing Phase 1 Trial with ADP-A2M4 Presented at ESMO
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented updated data from patients with synovial sarcoma who were treated in the ongoing Phase 1 trial with SPEAR T-cells targeting MAGE-A4 (ADP-A2M4). The...
Sep 09, 2019 08:00 am ET
United States Orphan Drug Designation for Treatment of Soft Tissue Sarcomas Granted to SPEAR T-cells Targeting MAGE-A4
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to SPEAR T-cells targeting MAGE-A4...
Aug 27, 2019 08:00 am ET
Adaptimmune and Noile-Immune Announce Agreement to Develop SPEAR T-Cell Products expressing IL-7 and CCL19 as a next-generation treatment for cancer patients
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, and Noile-Immune Biotech, Inc., Tokyo, Japan, a biotechnology company focusing on the development of innovative cancer immunotherapies, today announced that...
Aug 01, 2019 07:15 am ET
Adaptimmune Reports Second Quarter 2019 Financial Results and Business Update
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today reported financial results for the second quarter ended June 30, 2019 and...
Aug 01, 2019 07:15 am ET
New Executive Team Announced at Adaptimmune
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced changes to its Executive Team. In addition, the Company will report financial results for the Second Quarter 2019 and provide a business update...
Jul 29, 2019 04:05 pm ET
Adaptimmune to Report Second Quarter 2019 Financial Results and Business Update on Thursday, August 1, 2019
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will report financial results for the Second Quarter 2019 and provide a business update before the U.S. markets open on Thursday, August 1, 2019. Following the...
Jul 25, 2019 08:00 am ET
Adaptimmune Starts SPEARHEAD-1 Trial with ADP-A2M4 SPEAR T-cells for patients with Synovial Sarcoma or MRCLS
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, has started its SPEARHEAD-1 trial with ADP-A2M4 SPEAR T‑cells for patients with synovial sarcoma or myxoid/round cell liposarcoma (MRCLS). Earlier this year,...
Jul 22, 2019 08:00 am ET
Adaptimmune Has Initiated a Radiation Sub-Study to Enhance Antitumor Activity Seen With ADP-A2M4 in Collaboration with The MD Anderson Cancer Center
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, has initiated a radiation sub-study of its ADP‑A2M4 trial in collaboration with the University of Texas MD Anderson Cancer Center in Houston, TX. Published data...
Jul 18, 2019 08:00 am ET
Adaptimmune Starts the SURPASS Clinical Trial with its first Next-Generation SPEAR T-cells Targeting MAGE‑A4 to Enhance Antitumor Responses
Adaptimmune Therapeutics plc, Philadelphia, PA, and Oxfordshire, UK (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, has initiated SURPASS, its first clinical trial with a next-generation SPEAR T-cell targeting MAGE-A4. This...
Jun 27, 2019 08:00 am ET
Adrian Rawcliffe to Succeed James Noble as Adaptimmune Chief Executive Officer
Adaptimmune Therapeutics plc (Nasdaq:ADAP) today announced that Adrian Rawcliffe, currently Chief Financial Officer (CFO) of the Company, will succeed James Noble as Chief Executive Officer (CEO). This transition will occur when James retires from...
May 15, 2019 08:00 am ET
Adaptimmune and Alpine Immune Sciences Announce Collaboration and License Agreement to Develop Next-Generation SPEAR T-Cell Products
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, and Alpine Immune Sciences, Inc., Seattle, WA, (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatments for autoimmune diseases and...
May 06, 2019 07:30 am ET
Adaptimmune Reports First Quarter 2019 Financial Results
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today reported financial results for the first quarter ended March 31, 2019. Adaptimmune shared a clinical update in a separate release...
May 06, 2019 07:00 am ET
Significant Clinical Progress as Adaptimmune Announces Responses with ADP-A2M4 in Synovial Sarcoma and Antitumor Activity in Other Solid Tumors
PHILADELPHIA and OXFORD, United Kingdom, May 06, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced significant clinical progress with partial responses in 4 out of 5...
May 02, 2019 07:00 am ET
Adaptimmune to Present Data Demonstrating that its Off-the-shelf Process Produces T-cells from Stem Cells that Respond to Cancer Targets with a SPEAR TCR at ASGCT Meeting
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will present new and compelling data during an oral presentation about its off-the-shelf SPEAR T-cell program at the annual American Society of Gene & Cell...
May 01, 2019 08:00 am ET
Adaptimmune to Provide Clinical and Business Update on Monday May 6th, 2019
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will provide a clinical and business update before the U.S. markets open on Monday May 6, 2019. Following the announcement, the Company will host a live...
Apr 18, 2019 04:01 pm ET
Adaptimmune Announces Oral Presentation of Allogeneic SPEAR T-cell Program at 2019 ASGCT Meeting
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, announces an oral presentation by Dr. Jo Brewer, VP of Platform Sciences, summarizing data from Adaptimmune’s off‑the‑shelf SPEAR T-cell program at the American...
Apr 09, 2019 08:35 am ET
Market Trends Toward New Normal in Smartsheet, Spok, TPG RE Finance Trust, DSP Group, Adaptimmune Therapeutics, and Aquestive Therapeutics — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Smartsheet Inc. (NYSE:SMAR), Spok Holdings, Inc. (NASDAQ:SPOK), TPG RE Finance...
Apr 02, 2019 08:00 am ET
Adaptimmune Presents Safety Data with Evidence of Tumor Necrosis in One Patient from ADP-A2AFP Study at American Association for Cancer Research (AACR) Meeting
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented initial safety data from two patients with advanced hepatocellular carcinoma (HCC), liver cancer, from the first dose cohort of the ADP-A2AFP study...
Apr 01, 2019 08:00 am ET
Adaptimmune Presents Preclinical Data for its Next Generation SPEAR T-cell Targeting MAGE-A4 at the American Association for Cancer Research (AACR) Annual Meeting
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented promising preclinical data at the annual AACR meeting from its next generation SPEAR T-cell targeting MAGE-A4. This next generation SPEAR T-cell,...
Feb 27, 2019 07:29 am ET
Adaptimmune Reports Fourth Quarter / Full Year 2018 Financial Results and Business Update
Completed Cohort 1 for safety in ADP-A2AFP (AFP) study and treating patients in safety Cohort 2 at target doses of 1 billion cells - - Significant progress in cell and vector manufacturing internally as well as with external partners- -...
Feb 07, 2019 08:00 am ET
Adaptimmune to Report Fourth Quarter / Full Year 2018 Financial Results and Business Update on Wednesday, February 27, 2019
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the Fourth Quarter / Full Year 2018 and provide a general business update before the U.S. markets open on Wednesday,...
Jan 07, 2019 07:30 am ET
Dose Escalation in Liver Cancer Study with ADP-A2AFP (AFP) SPEAR T-cells and Moving to Expansion Phase in ADP-A2M10 (MAGE-A10) Lung Cancer Study after Favorable Safety Reviews
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the Safety Review Committee (SRC) has endorsed dose escalation in the ongoing ADP-A2AFP (AFP) study in patients with hepatocellular...
Dec 12, 2018 08:30 am ET
Adaptimmune Announces that Gwen Binder will leave in January 2019
Adaptimmune (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced that Gwen Binder, PhD, Chief Technology Officer, will be leaving the company at the end of January 2019. Dr. Binder was the first US employee of Adaptimmune in...
Nov 28, 2018 08:30 am ET
Recent Analysis Shows Bellicum Pharmaceuticals, NetEase, Nice, Match Group, SpartanNash, and Adaptimmune Therapeutics Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), NetEase, Inc....
Nov 06, 2018 07:30 am ET
Adaptimmune Reports Third Quarter 2018 Financial Results and Business Update
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today reported financial results for the third quarter ended September 30, 2018, and provided a business update. “We have now completed the three dose...
Oct 25, 2018 04:30 pm ET
Adaptimmune to Report Third Quarter 2018 Financial Results and Business Update on Tuesday, November 6, 2018
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the Third Quarter 2018 and provide a general business update before the U.S. markets open on Tuesday, November 6, 2018....
Oct 20, 2018 10:45 am ET
Updated Data from Ongoing MAGE-A10 and MAGE-A4 Studies Presented at the 2018 ESMO Congress
Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, presented initial data from the first two cohorts of its ongoing studies with its MAGE-A10 and MAGE-A4 SPEAR T-cells in two poster...
Oct 17, 2018 07:20 am ET
Investor Expectations to Drive Momentum within Arsanis, Dynavax Technologies, Puma Biotechnology, Opko Health, Adaptimmune Therapeutics, and Codexis — Discovering Underlying Factors of Influence
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Arsanis, Inc. (NASDAQ:ASNS), Dynavax Technologies Corporation...
Oct 08, 2018 06:10 pm ET
Data Updates from Ongoing MAGE-A10 Studies and MAGE-A4 Study to be presented at the European Society for Medical Oncology (ESMO) 2018 Congress
Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced further details about two poster presentations at the upcoming ESMO congress, as follows: MAGE-A10 poster for discussion...
Sep 07, 2018 01:14 pm ET
Adaptimmune Therapeutics plc Announces Closing of Registered Direct Offering of American Depositary Shares
Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced the closing of its previously announced registered direct offering of its American Depositary Shares (“ADSs”). Adaptimmune sold...
Sep 05, 2018 07:30 am ET
Adaptimmune Therapeutics plc Announces Registered Direct Offering of American Depositary Shares
Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced that it has entered into a definitive agreement with Matrix Capital Management Company, LP (“Matrix”), New Enterprise...
Aug 20, 2018 08:30 am ET
Investor Expectations to Drive Momentum within NEXEO SOLUTIONS, Altisource Portfolio Solutions S.A, Celestica, Star Bulk Carriers, Criteo S.A, and Adaptimmune Therapeutics — Discovering Underlying Fac
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of NEXEO SOLUTIONS (NASDAQ:NXEO), Altisource Portfolio Solutions S.A....
Aug 15, 2018 07:30 am ET
Third Dosing Cohort to be initiated in MAGE-A4 SPEAR T-cell Basket Study After Favorable Review of Safety from One Billion Cell Dose Cohort
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced a favorable review of safety data from the second dose cohort of patients who received one billion transduced SPEAR T‑cells targeting MAGE-A4 in...
Aug 02, 2018 07:30 am ET
Adaptimmune Reports Second Quarter 2018 Financial Results and Business Update
PHILADELPHIA and OXFORD, United Kingdom, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today reported financial results for the second quarter ended June 30, 2018, and...
Jul 26, 2018 01:18 pm ET
Adaptimmune to Report Second Quarter 2018 Financial Results and Business Update on Thursday August 2, 2018
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the Second Quarter 2018 and provide a general business update before the U.S. markets open on Thursday August 2, 2018....
Jul 24, 2018 07:30 am ET
GSK and Adaptimmune Complete Transition of NY-ESO SPEAR T-cell Therapy Program to GSK
GlaxoSmithKline plc and Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced the transition of the development program for GSK3377794 (GSK ‘794), an NY-ESO SPEAR T-cell therapy, to GSK. As a result...
Jul 18, 2018 07:29 am ET
Adaptimmune Announces Favorable Review of Safety from One Billion Cell Dose Cohort in MAGE-A10 SPEAR T-cell Study and Initiation of Third Dosing Cohorts
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced favorable review of safety data from the second dose cohort of patients who received one billion transduced SPEAR T‑cells targeting MAGE-A10 in...
Jun 11, 2018 07:30 am ET
Study published in Cancer Discovery Indicates that NY-ESO SPEAR T-cells are Long-lived, Self‑renewing, and Capable of Persistent Anti-Tumor Effects
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that data from the pilot study of NY-ESO SPEAR T‑cells in synovial sarcoma will be published in Cancer Discovery (an American Association of...
Jun 04, 2018 07:30 am ET
Adaptimmune Announces First Patient to Receive One Billion Target Cell Dose after Positive Safety Data from Pilot Study with MAGE-A4 SPEAR T-cells
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the independent safety review committee has recommended dose escalation in the MAGE-A4 basket study, based on an acceptable safety profile...
Jun 04, 2018 07:30 am ET
Adaptimmune Presents Detailed Safety Update from Ongoing MAGE-A10 Pilot Studies at ASCO
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented a safety update from its two ongoing pilot studies with SPEAR T-cells targeting MAGE-A10 in non-small cell lung cancer (NSCLC) and the triple tumor...
Jun 02, 2018 08:00 am ET
Updated Myxoid/Round Cell Liposarcoma Data with NY-ESO, Presented at ASCO Annual Meeting, Further Supports Promising Benefit: Risk Profile
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented initial data from the ongoing pilot study of NY-ESO SPEAR T-cells in myxoid/round cell liposarcoma (MRCLS). With eight patients treated, the best...
Jun 01, 2018 07:30 am ET
Investor Expectations to Drive Momentum within SK Telecom Co., Adaptimmune Therapeutics, Fiat Chrysler Automobiles N.V, Achillion Pharmaceuticals, Pzena Investment Management, and Sasol — Discovering
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of SK Telecom Co., Ltd. (NYSE:SKM), Adaptimmune Therapeutics PLC...
May 16, 2018 05:00 pm ET
Myxoid/Round Cell Liposarcoma Data with NY-ESO and MAGE-A10 Study Update to be Presented at American Association for Clinical Oncology (ASCO) Annual Meeting
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will release updated data from ongoing clinical studies at the annual ASCO meeting at McCormick Place in Chicago, Illinois. Data from the ongoing pilot study...
May 09, 2018 07:30 am ET
Adaptimmune Reports First Quarter 2018 Financial Results and Business Update
PHILADELPHIA and OXFORD, United Kingdom, May 09, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today reported financial results for the first quarter ended March 31, 2018, as well...
Apr 25, 2018 08:00 am ET
Adaptimmune to Report First Quarter 2018 Financial Results and Business Update on Wednesday May 9, 2018
PHILADELPHIA and OXFORD, U.K., April 25, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the First Quarter 2018 and provide a general business update before...
Apr 16, 2018 02:00 pm ET
Adaptimmune Presents MAGE-A4 and MAGE-A10 pre-clinical data at American Association for Cancer Research (AACR) Annual Meeting
- Preclinical testing raises no safety concerns for MAGE A4 -- Refined preclinical testing strategy expected to further mitigate risk of unexpected off-target toxicity -
Apr 12, 2018 08:00 am ET
Adaptimmune Announces Changes to Board of Directors
PHILADELPHIA, Pa. and OXFORD, U.K., April 12, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that, in a planned transition, John Furey has been appointed as an independent...
Apr 09, 2018 07:30 am ET
Report: Exploring Fundamental Drivers Behind Brookfield Property Partners, Grupo Financiero Galicia S.A, Adaptimmune Therapeutics, Radware, Mimecast, and Bandwidth — New Horizons, Emerging Trends, and
NEW YORK, April 09, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Brookfield Property Partners L.P. (NASDAQ:BPY), Grupo...
Apr 06, 2018 08:00 am ET
Adaptimmune to Present Two Posters at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
PHILADELPHIA, Pa. and OXFORD, U.K., April 06, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will present two posters summarizing preclinical research with its MAGE-A4 and MAGE-A10 SPEAR T-cells at the...
Mar 15, 2018 07:30 am ET
Adaptimmune Announces Responses in Second Solid Tumor Indication with NY-ESO SPEAR T-cells
Data provides confirmation of broad applicability of SPEAR TCR T-cell platform in solid tumors
Mar 15, 2018 07:30 am ET
Adaptimmune Reports Fourth Quarter / Full Year 2017 Financial Results and Business Update
- Responses observed in second solid tumor with NY-ESO providing further evidence of the potential of our SPEAR TCR T‑cell therapies to treat solid tumors -
Mar 13, 2018 07:30 am ET
Investor Expectations to Drive Momentum within Methanex, YPF Sociedad Anonima, Adaptimmune Therapeutics, Horizon Pharma, Changyou, and China Yuchai International — Discovering Underlying Factors of In
NEW YORK, NY, March 13, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Methanex Corporation (NASDAQ:MEOH), YPF Sociedad...
Mar 05, 2018 12:12 pm ET
Adaptimmune to Report Fourth Quarter / Full Year 2017 Financial Results and Business Update on Thursday March 15, 2018
PHILADELPHIA and OXFORD, United Kingdom, March 05, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the Fourth Quarter / Full Year 2017 and provide a general...
Jan 08, 2018 08:00 am ET
Adaptimmune Announces Positive Safety Data from Pilot Studies with MAGE-A10 SPEAR T-cells and First Patient to Receive 1 billion Target Cell Dose
PHILADELPHIA and OXFORD, United Kingdom, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced initial safety data from its two ongoing pilot studies of SPEAR T-cells targeting...
Jan 08, 2018 08:00 am ET
Adaptimmune Announces Two Manufacturing Achievements on Its way to Become the First Fully Integrated TCR T-cell Therapy Company
Successful Manufacturing of SPEAR T-cells for a Patient at its Navy Yard Site and Agreement with Cell and Gene Therapy Catapult to Increase Vector Manufacturing Capacity
Jan 04, 2018 08:00 am ET
Paul Stead Joins Adaptimmune as Vice President of Business Development
PHILADELPHIA, Pa. and OXFORD, England, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that Paul Stead, B. Pharm, PhD, MBA, MR PharmS has joined the Company...
Dec 11, 2017 04:46 pm ET
Adaptimmune Data Presented at American Society of Hematology (ASH) Annual Meeting for NY ESO SPEAR T-cells in Multiple Myeloma Pilot Study
PHILADELPHIA and OXFORD, United Kingdom, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, submitted updated data from its completed pilot study1 of NY‑ESO SPEAR T-cell therapy in multiple...
Dec 05, 2017 05:00 pm ET
Adaptimmune Data to be Presented at American Society of Hematology (ASH) Annual Meeting Confirm NY-ESO SPEAR T-cell Efficacy in Multiple Myeloma Pilot Study
PHILADELPHIA, Pa. and OXFORD, UK, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will have updated data from its completed pilot study1 of NY‑ESO SPEAR T-cell therapy in...
Nov 10, 2017 08:58 am ET
Adaptimmune Presents Study Designs for Ongoing MAGE-A4 and NY-ESO SPEAR T-cell Clinical Trials at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
PHILADELPHIA and OXFORD, U.K., Nov. 10, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, is presenting two trials in progress posters summarizing study designs for ongoing clinical trials with MAGE-A4...
Nov 09, 2017 08:00 am ET
NY-ESO Data Presented at the Connective Tissue Oncology Society (CTOS) Annual Meeting Confirm Potential of Adaptimmune’s SPEAR T-Cell Therapy
PHILADELPHIA and OXFORD, United Kingdom, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, released updated data from the ongoing pilot study of NY‑ESO SPEAR T-cells in synovial sarcoma,...
Nov 06, 2017 08:09 am ET
Adaptimmune marks Official Opening of U.K. Headquarters
Flagship Facility is new Base for U.K. Research and Development Operations
Nov 03, 2017 02:22 pm ET
Adaptimmune to Present Two Trials in Progress Posters at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
PHILADELPHIA and OXFORD, U.K., Nov. 03, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it will present two trials in progress posters at the 2017 SITC annual...
Nov 03, 2017 02:17 pm ET
Adaptimmune Data to be Presented in an Oral Presentation and a Trial in Progress Poster at the Connective Tissue Oncology Society (CTOS) Annual Meeting
PHILADELPHIA and OXFORD, U.K., Nov. 03, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that new data will be presented in an oral presentation and a trial in...
Nov 02, 2017 07:30 am ET
Adaptimmune Reports Third Quarter 2017 Financial Results and Business Updates
– GlaxoSmithKline plc (LSE/NYSE:GSK) exercised its option to license the right to research, develop, and commercialize Adaptimmune’s NY-ESO SPEAR T-cell therapy program –– Adaptimmune will receive up to $61 million from GSK over the course of the NY-ESO transition period,...
Oct 23, 2017 05:51 pm ET
Sébastien Desprez Joins Adaptimmune as Vice President of Communications and Investor Relations
PHILADELPHIA and OXFORD, U.K., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that Sébastien Desprez has joined the Company as Vice President of Communications and Investor Relations....
Aug 03, 2017 07:30 am ET
Adaptimmune Reports Second Quarter 2017 Financial Results
– A registered direct offering in April combined with a public offering in March raised net proceeds of $103.2 million; operations funded through to late 2019 –...
Jul 31, 2017 04:00 pm ET
Adaptimmune to Report Second Quarter 2017 Financial Results on August 3, 2017
PHILADELPHIA and OXFORD, United Kingdom, July 31, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer will announce financial results for the quarter ended June 30, 2017 before the open of the U.S. markets on Thursday, August 3, 2017....
May 03, 2017 04:01 pm ET
Adaptimmune to Report First Quarter 2017 Financial Results on May 10, 2017
PHILADELPHIA and OXFORD, U.K., May 03, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the quarter ended March 31, 2017 before the open of the U.S. markets on Wednesday May 10, 2017. Following the announcement, the company will host a live teleconference and webcast at 8:00 a.m. EST (1:00 p.m. BST) on the same day at which time management will provide a business update and discuss the financial results for the first quarter of 2017....
Mar 27, 2017 04:33 pm ET
Adaptimmune to Participate in Upcoming Jefferies Immuno-Oncology Summit
PHILADELPHIA and OXFORD, United Kingdom, March 27, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble, Adaptimmune’s Chief Executive Officer, and Gwen Binder-Scholl, Adaptimmune’s Chief Technology Officer, will be participating on an expert panel regarding cell therapy in solid tumors at the Jefferies Immuno-Oncology Summit on Thursday, March 30, 2017 at 11:45 AM EDT (4:45 PM BST). The conference is being held at the Boston Harbor Hotel in Boston, MA. Adaptimmune’s updated corporate presentatio...
Mar 21, 2017 04:54 pm ET
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
PHILADELPHIA and OXFORD, United Kingdom, March 21, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it intends to offer and sell American Depositary Shares (“ADSs”) in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Adaptimmune also expects to grant the underwriters a 30-day option to purchase additional ADSs at the public offering price. All of ...
Mar 02, 2017 08:00 am ET
Adaptimmune to Present at the Cowen and Company 37th Annual Health Care Conference
PHILADELPHIA and OXFORD, United Kingdom, March 02, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble, Adaptimmune’s Chief Executive Officer, will present at the Cowen and Company 37th Annual Health Care Conference on Tuesday March 7, 2017 at 10:40-11:10 AM EST (3:40-4:10 PM GMT). The conference is being held at the Boston Marriott Copley Plaza. Adaptimmune’s presentation will be webcast live for investors through the investor section of www.adaptimmune.com and available for a period of 30 days fol...
Jan 09, 2017 08:01 am ET
Adaptimmune Announces New Senior Vice President of Global Bio-Process and Development
PHILADELPHIA and OXFORD, United Kingdom, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that Mark E. Dudley, Ph.D. has joined the company as Senior Vice President of Global Bio-Process and Development....

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.